Teva, Sanofi say bowel disease drug met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...
Teva, Sanofi say bowel disease drug met primary targets (Dec 17)
Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping ...
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, ...
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 ...
Teva, Sanofi say drug to treat IBD met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...
FierceBiotech1d
Sanofi, Teva look to 'next frontier' in IBD treatment after TL1A antibody hits mark in midstage trial
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
GlobalData on MSN1d
Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial
Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody ...
Sanofi, Teva say study results show gut disease drug could be ‘best in class’
Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and ...
Teva, Sanofi Say IBD Treatment Achieved Higher Remission at Trial
The companies said Tuesday that patients with ulcerative colitis who were treated with duvakitug achieved a higher rate of clinical remission compared with a placebo group. A group of patients with ...
Pharmabiz5h
Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints
Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints: Paris Thursday, December 19, 2024, 11:00 Hrs ...
pharmaphorum1d
Teva, Sanofi score well with anti-TL1A drug in IBD test
The TL1A drug would serve as a companion to Sanofi and partner Regeneron's multibillion-dollar blockbuster Dupixent ...